“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy
Open Access
- 14 May 2016
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 11 (10), e117-e119
- https://doi.org/10.1016/j.jtho.2016.05.002
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung CancerJournal of Thoracic Oncology, 2016
- Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areasEuropean Journal Of Cancer, 2015
- Pseudoprogression and Immune-Related Response in Solid TumorsJournal of Clinical Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015